Previous literature has showed successful results of dupilumab on hand eczema in patients treated for AD1 and in individuals with isolated vesicular hand eczema.2, 4 In view of the good effect of dupilumab on HHE as well, it might be hypothesized that, despite the differences in phenotype, there are similarities in endotype and underlying pathogenesis with an IL‐4/IL‐13 driven inflammation between different subtypes of hand eczema. Here, IL13 is linked to Alzheimer disease type 1.